{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:53:32Z","timestamp":1784238812720,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The periorbital region is among the first areas noticed in an individual, playing a crucial role in facial attractiveness and emotional expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Open\u2010label study to evaluate the impact of mid and upper facial treatment with hyaluronic acid (HA) fillers and onabotulinumtoxinA (onabotA) on periorbital satisfaction and appearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients\/Methods<\/jats:title>\n                    <jats:p>Eligible participants received \u2265\u20092 HA fillers (VYC\u201015L, VYC\u201017.5L, VYC\u201020L) in the mid and upper face on Day 1, and VYC\u201015L in the infraorbital hollow (IOH) on Day 30 if needed. Optional touch ups followed after 14\u2009days. OnabotA was administered to glabellar lines (GL) and\/or lateral canthal lines (LCL) on Day 60. The primary endpoint was the change from baseline in FACE\u2010Q Satisfaction with Eyes to Day 90. Additional effectiveness assessments and safety were monitored throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Enrolled participants were 86.3% White and 13.7% Asian. FACE\u2010Q Rasch\u2010transformed scores increased from baseline to Day 90 by 55.5 points (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Investigator\u2010assessed infraorbital appearance improved in 69.4% of participants at Day 30 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.063 vs. baseline) and in 100% at Day 90. Periorbital appearance improved in 91.7% (investigator) and 95.8% (participant) of participants at Day 30, reaching 100% for both at Day 90 (nominal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 vs. baseline). IOH severity gradually decreased, with 59.8% of participants showing minimal or no severity at Day 90 versus 0% at baseline, and infraorbital volume increased. No unexpected safety signals were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combination of HA fillers and onabotA treatments improved eye satisfaction, periorbital and infraorbital appearance, IOH severity, and infraorbital volume, demonstrating direct and indirect treatment effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.70487","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:27:39Z","timestamp":1761071259000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improved Periorbital Satisfaction After Combined Mid and Upper Facial Treatment With Hyaluronic Acid Fillers and\n                    <scp>OnabotulinumtoxinA<\/scp>\n                    : Effectiveness and Safety Results From a Post\u2010Marketing Study"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-9690","authenticated-orcid":false,"given":"Gregory J.","family":"Goodman","sequence":"first","affiliation":[{"name":"Department of General Practice Monash University  Clayton Australia"},{"name":"University College of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3064-8437","authenticated-orcid":false,"given":"Pierre","family":"Cuvelier","sequence":"additional","affiliation":[{"name":"Centre de La Fontaine  Loverval Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2892-3930","authenticated-orcid":false,"given":"Frank","family":"Lin","sequence":"additional","affiliation":[{"name":"Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6874-6816","authenticated-orcid":false,"given":"Cara","family":"McDonald","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-0067","authenticated-orcid":false,"given":"Sarah","family":"Boxley","sequence":"additional","affiliation":[{"name":"SkinBox Clinics  Perth Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Vandeputte","sequence":"additional","affiliation":[{"name":"Private Practice  Oudenaarde Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-7724","authenticated-orcid":false,"given":"Ivar Van","family":"Heijningen","sequence":"additional","affiliation":[{"name":"Duinbergen Clinic  Knokke\u2010Heist Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-7768","authenticated-orcid":false,"given":"Samira","family":"Baharlou","sequence":"additional","affiliation":[{"name":"Skin Immunology &amp; Immune Tolerance (SKIN) Research Group Vrije Universiteit Brussel (VUB)  Brussels Belgium"},{"name":"Department of Dermatology Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel)  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Baker","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Chawla","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"de la Guardia","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cps.2012.08.005"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjaa339"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12082"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab114"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12514"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjv050"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001684"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000007857"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.asj.2005.09.012"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac267"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13728"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20101953\u20102304"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032496"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032375"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104725.2010.01705.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529\u20108019.2006.00072.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjx179"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000002119"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2016.1018"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000856"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000008366"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab257"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjae073"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab308"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojad016"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15787"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266\u2010020\u201001808\u2010w"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266\u2010016\u20100608\u2010y"},{"key":"e_1_2_11_30_1","unstructured":"\u201cJuv\u00e9derm VOLBELLA With Lidocaine 32G Directions for Use. 73363JR10 \u201dRevision 2020\u201007\u201010."},{"key":"e_1_2_11_31_1","unstructured":"\u201cJuv\u00e9derm VOLIFT With Lidocaine Diections for Use. 73652JR10 \u201dRevision 2019\u201009\u201009."},{"key":"e_1_2_11_32_1","unstructured":"\u201cJuv\u00e9derm VOLUMA With Lidocaine Direction for Use. 73650JR10 \u201dRevision 2019\u201009\u201009."},{"key":"e_1_2_11_33_1","unstructured":"\u201cVistabel Summary of Product Characteristics \u201dAbbVie Ltd. Medicines.ie accessed February 24 2025 https:\/\/www.medicines.ie\/medicines\/vistabel\u201034207\/spc."},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/app112311489"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100041\u20101731348"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266\u2010017\u20101063\u20100"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100041\u20101741560"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T02:18:48Z","timestamp":1764641928000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/jocd.70487"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70487","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70487"}}